gallium-68

gallium-68 is a radioactive isotope of the element gallium that has emerged as a crucial tool in modern nuclear medicine. It decays primarily via positron emission, making it an ideal source for positron emission tomography imaging. The isotope is typically obtained from a germanium-68/gallium-68 generator system, enabling its use in hospitals without an on-site cyclotron. Its chemistry allows it to form stable complexes with various chelating agents, facilitating its incorporation into targeted radiopharmaceuticals for diagnosing diseases like neuroendocrine tumors and prostate cancer.

Properties

Gallium-68 has an atomic mass of approximately 68 amu and a half-life of 67.71 minutes. Its primary decay mode is positron emission with a maximum energy of 1.899 MeV, accompanied by a minor branch of electron capture. The emitted positrons annihilate with nearby electrons, producing two 511 keV gamma rays detected in PET scans. The isotope also emits Auger electrons, which are of interest for potential targeted radionuclide therapy. Its chemical behavior is defined by the +3 oxidation state, similar to ferric ion, allowing it to form strong complexes with ligands like DOTA and NOTA.

Production

The most common production method utilizes a germanium-68/gallium-68 generator, where the long-lived parent isotope germanium-68 decays via electron capture to yield gallium-68. This system, often based on tin dioxide or titanium dioxide columns, allows for simple elution with hydrochloric acid, providing a sterile, pyrogen-free solution suitable for clinical use. Gallium-68 can also be produced directly in a cyclotron by bombarding a zinc-68 target with protons, though the generator method dominates due to its convenience. Research into alternative production routes includes using liquid targets at facilities like the TRIUMF laboratory in Canada.

Medical applications

The principal medical application of gallium-68 is as a positron-emitting tracer for positron emission tomography. It is particularly valuable in oncology for imaging somatostatin receptor overexpression in neuroendocrine tumors, using compounds like Ga-68 DOTATATE. It is also central to PSMA PET imaging for staging prostate cancer with agents such as Ga-68 PSMA-11. Beyond oncology, it is used in imaging infection and inflammation via Ga-68 citrate, and in cardiology for assessing myocardial perfusion. The development of these applications has been advanced by organizations like the European Association of Nuclear Medicine.

Radiopharmaceuticals

Gallium-68 radiopharmaceuticals are synthesized by complexing the eluted gallium-68 cation with a bifunctional chelator that is pre-conjugated to a targeting molecule. Common chelators include DOTA, HBED-CC, and NOTA, which form thermodynamically stable and kinetically inert complexes. Leading targeted agents include Ga-68 DOTATOC and Ga-68 DOTANOC for neuroendocrine tumors, and Ga-68 PSMA-617 for prostate cancer. The kit-based formulation of Ga-68 GO-SPRITE for fibroblast activation protein imaging represents a recent innovation. Quality control is paramount and involves techniques like radio-TLC and HPLC to ensure radiochemical purity.

Safety and handling

Handling gallium-68 requires strict adherence to ALARA principles due to its gamma ray and positron emissions. Work must be conducted in appropriate lead or tungsten shielded hot cells or synthesis modules, often under Good Manufacturing Practice conditions. Personnel monitoring with dosimeters is mandatory. The short half-life limits long-term radioactive waste concerns, but waste must be stored for decay-in-storage, typically for about ten half-lives, before disposal as biological waste. Regulatory oversight is provided by bodies such as the U.S. Food and Drug Administration and the European Medicines Agency.

Category:Gallium Category:Positron emission tomography Category:Medical isotopes